BRCA2 and neoplasm: Based on few therapeutic options for recurrent platinum-taxane resistant HGSOC without BRCA1/BRCA2 mutations or HRD, we sought to test the hypothesis that inhibiting aurora A kinase (AAK) with AL and interfering with G2-M transition would enhance the anti-tumor activity of cisplatin (CP) or paclitaxel (PT).